289 related articles for article (PubMed ID: 34004261)
1. Exploration of the potential mechanism of Banxia Xiexin Decoction for the effects on TNBS-induced ulcerative colitis rats with the assistance of network pharmacology analysis.
Wang W; Xu C; Li X; Wang Z; Yang J; Shen Y; Shi M; Chen L; Zhang L; Guo Y; Wang B; Zhang T; Pu Y
J Ethnopharmacol; 2021 Sep; 277():114197. PubMed ID: 34004261
[TBL] [Abstract][Full Text] [Related]
2. Banxia Xiexin decoction modulates gut microbiota and gut microbiota metabolism to alleviate DSS-induced ulcerative colitis.
Luo Y; Fu S; Liu Y; Kong S; Liao Q; Lin L; Li H
J Ethnopharmacol; 2024 May; 326():117990. PubMed ID: 38423412
[TBL] [Abstract][Full Text] [Related]
3. Banxia xiexin decoction protects against dextran sulfate sodium-induced chronic ulcerative colitis in mice.
Chen G; Yang Y; Liu M; Teng Z; Ye J; Xu Y; Cai X; Cheng X; Yang J; Hu C; Wang M; Cao P
J Ethnopharmacol; 2015 May; 166():149-56. PubMed ID: 25794808
[TBL] [Abstract][Full Text] [Related]
4. Banxia Xiexin decoction ameliorates dextran sulfate sodium (DSS)-induced ulcerative colitis via inhibiting serine-threonine protein kinase (Akt)/mitogen-activated protein kinase (MAPK) signaling pathway.
Ji W; Liu W; Huo Y; Hu C; Zhang Y
Biotechnol Appl Biochem; 2023 Aug; 70(4):1530-1542. PubMed ID: 36806191
[TBL] [Abstract][Full Text] [Related]
5. Bioactive components of Banxia Xiexin Decoction for the treatment of gastrointestinal diseases based on flavor-oriented analysis.
Wang W; Gu W; He C; Zhang T; Shen Y; Pu Y
J Ethnopharmacol; 2022 Jun; 291():115085. PubMed ID: 35150814
[TBL] [Abstract][Full Text] [Related]
6. [Effect of Banxia Xiexin Decoction on intestinal flora of mice with ulcerative colitis induced by dextran sodium sulfate].
Chen J; Zhang LK; Gu WC; Zhang XS; Li L; Han T; Liu XJ; Huang HL
Zhongguo Zhong Yao Za Zhi; 2021 Jun; 46(11):2871-2880. PubMed ID: 34296588
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the pharmacological mechanism of Banxia Xiexin decoction in treating depression and ulcerative colitis based on a biological network module.
Yu Y; Zhang G; Han T; Huang H
BMC Complement Med Ther; 2020 Jun; 20(1):199. PubMed ID: 32600331
[TBL] [Abstract][Full Text] [Related]
8. Identifying the active compounds and mechanism of action of Banxia Xiexin decoction for treating ethanol-induced chronic gastritis using network pharmacology combined with UPLC-LTQ-Orbitrap MS.
Ji W; Wang T; Xu Y; An R; Liang K; Wang X
Comput Biol Chem; 2021 Aug; 93():107535. PubMed ID: 34217946
[TBL] [Abstract][Full Text] [Related]
9. Banxia Xiexin decoction combined with 5-ASA protects against CPT-11-induced intestinal dysfunction in rats via inhibiting TLR4/NF-κB signaling pathway.
Zou Y; Wang Y; Zhou W; Pei J
Immun Inflamm Dis; 2024 Jun; 12(6):e1208. PubMed ID: 38860759
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of Patrinia villosa on TNBS-induced ulcerative colitis via metabolism, vitamin D receptor and NF-κB signaling pathways.
Wang J; Wang X; Ma X; Xu B; Chen L; Chen C; Liu W; Liu Y; Xiang Z
J Ethnopharmacol; 2022 Apr; 288():114989. PubMed ID: 35032589
[TBL] [Abstract][Full Text] [Related]
11. Identification of the bioactive components of Banxia Xiexin Decoction that protect against CPT-11-induced intestinal toxicity via UPLC-based spectrum-effect relationship analyses.
Shi JW; Li ZZ; Wu JS; Jin WY; Chang XY; Sun H; Dong L; Jiang ZP; Shi Y
J Ethnopharmacol; 2021 Feb; 266():113421. PubMed ID: 33022337
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammation effect of Qingchang suppository in ulcerative colitis through JAK2/STAT3 signaling pathway in vitro and in vivo.
Yu T; Li Z; Xu L; Yang M; Zhou X
J Ethnopharmacol; 2021 Feb; 266():113442. PubMed ID: 33027643
[TBL] [Abstract][Full Text] [Related]
13. Active components alignment of Gegenqinlian decoction protects ulcerative colitis by attenuating inflammatory and oxidative stress.
Xu BL; Zhang GJ; Ji YB
J Ethnopharmacol; 2015 Mar; 162():253-60. PubMed ID: 25557032
[TBL] [Abstract][Full Text] [Related]
14. [Potential molecular mechanism of Banxia Xiexin Decoction in treatment of colon cancer based on network pharmacology and molecular docking technology].
Luo YT; Lin LF; Liu YL; Shi GL; Wu YQ; Yang AH; Li H
Zhongguo Zhong Yao Za Zhi; 2020 Dec; 45(23):5753-5761. PubMed ID: 33496116
[TBL] [Abstract][Full Text] [Related]
15. Integrated Network Pharmacology, Molecular Docking and Animal Experiment to Explore the Efficacy and Potential Mechanism of Baiyu Decoction Against Ulcerative Colitis by Enema.
Cui Y; Hu J; Li Y; Au R; Fang Y; Cheng C; Xu F; Li W; Wu Y; Zhu L; Shen H
Drug Des Devel Ther; 2023; 17():3453-3472. PubMed ID: 38024534
[TBL] [Abstract][Full Text] [Related]
16. Banxia Xiexin Decoction delays colitis-to-cancer transition by inhibiting E-cadherin/β-catenin pathway via Fusobacterium nucleatum FadA.
Jiang Y; Huang Y; Hu Y; Yang Y; You F; Hu Q; Li X; Zhao Z
J Ethnopharmacol; 2024 Jun; 328():117932. PubMed ID: 38382652
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the Active Ingredients and Mechanism of Hudi Enteric-Coated Capsules in DSS-Induced Ulcerative Colitis Mice Based on Network Pharmacology and Experimental Verification.
Ding P; Liu J; Li Q; Lu Q; Li J; Shi R; Shi L; Mao T; Ge D; Niu H; Peng G; Wang Z
Drug Des Devel Ther; 2021; 15():4259-4273. PubMed ID: 34675488
[TBL] [Abstract][Full Text] [Related]
18. [Banxia Xiexin Decoction inhibiting colitis-associated colorectal cancer infected with Fusobacterium nucleatum by regulating Wnt/β-catenin pathway].
Jiang YF; Huang YQ; Hu YE; Yang Y; Zheng C; You FM; Zhao ZY
Zhongguo Zhong Yao Za Zhi; 2024 Mar; 49(5):1266-1274. PubMed ID: 38621974
[TBL] [Abstract][Full Text] [Related]
19. Exploring the multicomponent synergy mechanism of Banxia Xiexin Decoction on irritable bowel syndrome by a systems pharmacology strategy.
Li B; Rui J; Ding X; Yang X
J Ethnopharmacol; 2019 Apr; 233():158-168. PubMed ID: 30590198
[TBL] [Abstract][Full Text] [Related]
20. Banxia Xiexin Decoction () Treats Diabetic Gastroparesis through PLC-IP
Wang B; Zeng KW; Hong ZF; Ti GX; Wang LY; Lu P; Liu Z
Chin J Integr Med; 2020 Nov; 26(11):833-838. PubMed ID: 32418177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
